Dr. Sulaiman Al Habib Medical Services Group (4013) Fair Value & Analysis
Healthcare · SA · Market cap 81.9B SAR
Fair value as of: Aug 13, 2026
From 22 valuation models · updated yesterday
Share price +10.8% over the past month.
A solid business, but screening 52% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (213.99 SAR). The favourable scenario is already priced in.
- The model range is unusually wide (49.04 SAR to 213.99 SAR). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 118.94 SAR – 322.29 SAR · fair‑value band 49.04 SAR – 213.99 SAR · the 235.00 SAR price screens above the 112.37 SAR fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Dr. Sulaiman Al Habib Medical Services Group (4013) currently trades at 235.00 SAR, while our model-based Fair Value estimate is 112.37 SAR, implying the stock looks roughly 52.2% overvalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Dr. Sulaiman Al Habib Medical Services Group generated revenue of 14.6B SAR at a net margin of 16.6%. Revenue grew 18.4% year over year. It earns a return on equity of 30.1%. Net debt stands at 7.0B SAR. Fundamentals as of Aug 13, 2026
Our scenario range runs from 49.04 SAR (bear case) to 213.99 SAR (bull case); at 235.00 SAR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 15% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -52%, 4013 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 22 models by family
Widest divergence: Growth Earnings (164.61 SAR) versus Asset-Based (15.13 SAR). Highest evidence: Residual Income (76).
Notify me when 4013 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 53 · Market factors (momentum, volatility) 49
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Dr. Sulaiman Al Habib Medical Services Group Company, together with its subsidiaries, provides private health and support services in the Kingdom of Saudi Arabia. It operates through three segments: Hospitals/Healthcare Facilities, Pharmacies, and Other Solutions Sector.
Full company description
Dr. Sulaiman Al Habib Medical Services Group Company, together with its subsidiaries, provides private health and support services in the Kingdom of Saudi Arabia. It operates through three segments: Hospitals/Healthcare Facilities, Pharmacies, and Other Solutions Sector. The company establishes, manages, and operates hospitals, general and specialized medical complexes, day surgery centers, and pharmaceutical facilities. It also provides home medical care; specialized medical laboratories; information technology and systems; facility maintenance; telemedicine; revenue cycle management; and medical equipment maintenance services, as well as engages in real estate activities. The company was founded in 1993 and is based in Riyadh, the Kingdom of Saudi Arabia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Dr. Sulaiman Al Habib Medical Services Group reported revenue of 13.7B SAR in FY2025 versus 7.3B SAR in FY2021, a compound +17.3%/yr. Reported net income was 2.4B SAR in FY2025, compounding +14.9%/yr from FY2021.
of which total revenue +10.3 pp · buybacks/dilution +0.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
4013 screens 52% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 265 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $414.59 | $547.67 | +32% |
| Fresenius SE FRE | €46.82 | €32.15 | -31% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | -46% |
| Tenet Healthcare Corporation THC | $266.79 | $330.25 | +24% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.97 | R$47.31 | +39% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,565 | ₹2,955 | -65% |
| Aier Eye Hospital Group 300015 | ¥8.87 | ¥7.67 | -14% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,008 | ₹284.87 | -72% |
| Bangkok Dusit Medical Services Public Company BDMS | 19.70 THB | 18.57 THB | -6% |
| Fortis Healthcare Limited FORTIS | ₹906.15 | ₹300.29 | -67% |
Compare Dr. Sulaiman Al Habib Medical Services Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Dr. Sulaiman Al Habib Medical Services Group (4013) overvalued or undervalued?
What is the fair value of 4013?
What is the quality score of 4013?
What is the revenue of Dr. Sulaiman Al Habib Medical Services Group (4013)?
What is the net profit margin of 4013?
Does Dr. Sulaiman Al Habib Medical Services Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Dr. Sulaiman Al Habib Medical Services Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.